CXCR4 Based Therapeutics for Non-Small Cell Lung Cancer (NSCLC).

ABSTRACT: Lung cancer is the second most common malignancy. Unfortunately, despite advances in multimodality therapeutics for the disease, the overall five-year survival rate among newly diagnosed lung cancer patients remains in the range region of 15%. In addition, although immune checkpoint inhibitors are increasingly being incorporated into lung cancer treatment protocols, the proportion of patients that respond to these agents remains low and the duration of response is often short. Therefore, novel methodologies to enhance the efficacy of immunotherapy in lung cancer are highly desirable. Chemokines are small chemotactic cytokines that interact with their 7 transmembrane G-protein⁻coupled receptors, to guide immune cell trafficking in the body under both physiologic and pathologic conditions. T

SUBMITTER: Wald O 

PROVIDER: S-EPMC6210654 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature